Published in Clin Chem on October 01, 2001
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
PET Imaging of Tau Deposition in the Aging Human Brain. Neuron (2016) 2.01
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol (2010) 1.59
Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J Neurol (2012) 1.20
Cerebrospinal fluid markers in Creutzfeldt-Jakob disease. Cerebrospinal Fluid Res (2008) 1.17
The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging (2007) 1.07
Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS. PLoS One (2014) 1.00
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain (2015) 0.92
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med (2012) 0.90
Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol (2014) 0.90
The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis (2012) 0.89
Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol (2010) 0.89
White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults. Neurobiol Aging (2014) 0.87
The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol (2010) 0.87
Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement (2013) 0.86
Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study. Alzheimers Res Ther (2014) 0.86
Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues Clin Neurosci (2009) 0.86
Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. Dement Geriatr Cogn Dis Extra (2013) 0.86
Reduced CSF turnover and decreased ventricular Aβ42 levels are related. BMC Neurosci (2011) 0.86
Medial temporal atrophy in early and late-onset Alzheimer's disease. Neurobiol Aging (2014) 0.85
Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. Neurol Sci (2011) 0.84
Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. J Neurol (2011) 0.84
Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study. PLoS One (2013) 0.84
Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates. Behav Brain Funct (2010) 0.83
Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. World J Psychiatry (2011) 0.81
White matter integrity and cognition in Parkinson's disease: a cross-sectional study. BMJ Open (2014) 0.80
CSF phospho-tau is independent of age, cognitive status and gender of neurological patients. J Neurol (2009) 0.80
Increased concentration of the CSF Tau protein and its phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case report. J Neural Transm (Vienna) (2012) 0.80
Expression of Tau40 induces activation of cultured rat microglial cells. PLoS One (2013) 0.80
Bivariate correlation coefficients in family-type clustered studies. Biom J (2015) 0.80
Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease. Front Aging Neurosci (2017) 0.79
A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease. J Clin Neurol (2015) 0.79
CSF tau and β-amyloid as biomarkers for mild cognitive impairment. Dialogues Clin Neurosci (2004) 0.79
Alzheimer's Biomarkers are Correlated with Brain Connectivity in Older Adults Differentially during Resting and Task States. Front Aging Neurosci (2016) 0.78
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther (2016) 0.78
Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis. Front Aging Neurosci (2014) 0.77
Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. J Parkinsons Dis (2016) 0.77
Differential white matter connectivity in early mild cognitive impairment according to CSF biomarkers. PLoS One (2014) 0.77
First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. PLoS One (2015) 0.77
Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm (Vienna) (2010) 0.77
Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia. J Neurol (2007) 0.76
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. Ups J Med Sci (2012) 0.76
Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease. J Alzheimers Dis Parkinsonism (2014) 0.76
Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting. Dement Geriatr Cogn Dis Extra (2016) 0.75
The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimers Dement (Amst) (2016) 0.75
Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study. Dement Geriatr Cogn Dis Extra (2017) 0.75
Reference Intervals for Plasma Amyloid β in Korean Adults Without Cognitive Impairment. Ann Lab Med (2016) 0.75
Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β1-42 and total tau. Transl Neurosci (2013) 0.75
Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea. Alzheimer Dis Assoc Disord (2016) 0.75
Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults. Front Aging Neurosci (2017) 0.75
Lateral ventricular cerebrospinal fluid diffusivity as a potential neuroimaging marker of brain temperature in multiple sclerosis: a hypothesis and implications. Magn Reson Imaging (2014) 0.75
Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex. J Neurodegener Dis (2013) 0.75
The presenilin 1 P264L mutation presenting as non-fluent/agrammatic primary progressive aphasia. J Alzheimers Dis (2013) 0.75
Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. Brain Behav (2017) 0.75
A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers. J Alzheimers Dis (2017) 0.75
Tau protein as a possible marker of cerebrospinal fluid leakage in cerebrospinal fluid rhinorrhoea: A pilot study. Biochem Med (Zagreb) (2017) 0.75
A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. Neurol Ther (2017) 0.75
Tau missing from CSF: a case report. J Neurol (2007) 0.75
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Alzheimers Res Ther (2017) 0.75
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 7.43
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology (1999) 4.37
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol (1995) 3.23
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett (1995) 3.15
Development of the EURO-D scale--a European, Union initiative to compare symptoms of depression in 14 European centres. Br J Psychiatry (1999) 3.13
A 24-year follow-up of body mass index and cerebral atrophy. Neurology (2004) 2.91
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A (1999) 2.82
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl (2000) 2.56
Burden of illness and suicide in elderly people: case-control study. BMJ (2002) 2.51
Normal pressure hydrocephalus: vascular white matter changes on MR images must not exclude patients from shunt surgery. AJNR Am J Neuroradiol (2001) 2.46
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]. Arch Gen Psychiatry (1999) 2.31
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Onset of terminal decline in cognitive abilities in individuals without dementia. Neurology (2008) 2.24
Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res (2001) 2.19
Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem (1993) 2.18
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology (2005) 2.07
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry (2000) 1.97
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem (1996) 1.89
Incidence of ROP in two consecutive Swedish population based studies. Br J Ophthalmol (2002) 1.86
CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand (2007) 1.85
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J (1994) 1.85
Depressive symptoms and risk of stroke: the Rotterdam Study. J Neurol Neurosurg Psychiatry (2008) 1.84
CT and MRI rating of white matter lesions. Cerebrovasc Dis (2002) 1.83
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Specific Neisseria gonorrhoeae DNA-probes derived from ribosomal RNA. J Gen Microbiol (1989) 1.82
Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve. J Cell Biol (1993) 1.78
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand (1991) 1.77
Depression symptoms in late life assessed using the EURO-D scale. Effect of age, gender and marital status in 14 European centres. Br J Psychiatry (1999) 1.75
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Regional brain enlargement in autism: a magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry (1996) 1.70
Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol (1999) 1.68
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology (2010) 1.64
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol (2009) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport (2001) 1.63
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry (1999) 1.61
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry (2003) 1.58
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry (2003) 1.58
Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. Eur Respir J (2005) 1.56
Morphometry in schizophrenia revisited: height and its relationship to pre-morbid function. Psychol Med (1998) 1.56
Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord (1998) 1.55
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
The clinical effect of lumbar puncture in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry (1982) 1.51
CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol (2002) 1.51
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
Little evidence for different phenomenology in poststroke depression. Acta Psychiatr Scand (2010) 1.50